Dihydropyrimidine Dehydrogenase Deficiency Latest Advances

Find the Latest Research About Dihydropyrimidine Dehydrogenase Deficiency

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 303 publications

Dihydropyrimidine dehydrogenase testing: capturing what standard genotyping misses with next-generation sequencing.

Dihydropyrimidine dehydrogenase testing: capturing what standard genotyping misses with next-generation sequencing.

Journal: Pharmacogenomics
Published: January 16, 2026

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Journal: Expert opinion on drug metabolism & toxicology
Published: January 08, 2026

Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.

Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.

Journal: JCO global oncology
Published: November 19, 2025

Functional studies of human variants in C. elegans link iron metabolism to DPD deficiency and 5-FU sensitivity.

Functional studies of human variants in C. elegans link iron metabolism to DPD deficiency and 5-FU sensitivity.

Journal: Genetics
Published: September 15, 2025

Suspected capecitabine-induced fatal toxicity in the context of a new DPYD variant.

Suspected capecitabine-induced fatal toxicity in the context of a new DPYD variant.

Journal: BMJ case reports
Published: August 31, 2025

A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.

A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.

Journal: Journal of the National Cancer Institute
Published: August 25, 2025

Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing.

Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing.

Journal: JCO precision oncology
Published: July 10, 2025

A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines.

A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines.

Journal: International journal of molecular sciences
Published: July 05, 2025

Clinical implementation and outcome evaluation of dihydropyrimidine dehydrogenase (DPYD) pharmacogenomic testing for fluoropyrimidine dosing in a Canadian Provincial Healthcare center.

Clinical implementation and outcome evaluation of dihydropyrimidine dehydrogenase (DPYD) pharmacogenomic testing for fluoropyrimidine dosing in a Canadian Provincial Healthcare center.

Journal: Clinical biochemistry
Published: June 15, 2025

Clinical Implications of a Large-Scale Voluntary Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine: Preliminary Results.

Clinical Implications of a Large-Scale Voluntary Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine: Preliminary Results.

Journal: JCO oncology practice
Published: June 12, 2025

Phenotyping and genotyping for the dihydropyrimidine dehydrogenase test in Italy: a precise diagnostic strategy to detect rare variants and improve drug administration.

Phenotyping and genotyping for the dihydropyrimidine dehydrogenase test in Italy: a precise diagnostic strategy to detect rare variants and improve drug administration.

Journal: Clinical biochemistry
Published: May 17, 2025

A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity.

A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity.

Journal: Cancer chemotherapy and pharmacology
Published: April 30, 2025
Showing 1-12 of 303

Last Updated: 02/24/2026